Compare · CSTL vs ELV
CSTL vs ELV
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.50B, about 80.9x CSTL ($1.07B).
- CSTL has hit the wire 12 times in the past 4 weeks while ELV has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $1.07B
- $86.50B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 0
- Recent ratings
- 6
- 23
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CSTL
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Chief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)
- Chief Financial Officer Stokes Frank sold $741,511 worth of shares (24,908 units at $29.77), decreasing direct ownership by 41% to 35,177 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 1,100 shares at a strike of $2.39 and sold $217,105 worth of shares (7,232 units at $30.02) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 8-A12B filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $49,945 worth of shares (1,301 units at $38.39) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 77,694 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 22,902 shares at a strike of $2.39 and sold $1,212,230 worth of shares (39,016 units at $31.07) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Oelschlager Kristen M sold $255,622 worth of shares (8,586 units at $29.77) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 13,288 units (SEC Form 4)
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS